A Phase I Study of JSKN021 in Advanced Solid Tumors
24. august 2026 opdateret af: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors
This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
199
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Jian Zhang, MD
- Telefonnummer: 08602134778299
- E-mail: syner2000@163.com
Studiesteder
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekruttering
- Fujian Cancer Hospital
-
-
Guangxi
-
Nanning, Guangxi, Kina
- Rekruttering
- Tumor Hospital of Guangxi Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina
- Rekruttering
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, Hubei, Kina, 430079
- Rekruttering
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Rekruttering
- Jiangsu Province Hospital
-
Xuzhou, Jiangsu, Kina
- Rekruttering
- Xuzhou Central Hospital
-
-
Shandong
-
Jining, Shandong, Kina
- Rekruttering
- Affiliated Hospital of Jining Medical College
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Rekruttering
- Fudan University Shanghai Cancer Center
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300060
- Rekruttering
- Tianjin Medical University Cancer Institute & Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Voluntarily participate and sign the informed consent form.
- Age ≥ 18 years old, male or female.
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
- Expected survival ≥ 3 months.
- Histologically or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
- At least one measurable lesion at baseline according to RECIST 1.1 criteria.
- Adequate organ function.
- Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use effective contraceptive measures.
- Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
- Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
- Adequate washout period of previous therapy before the first dose.
Exclusion Criteria:
- Complicated with other malignant tumors within 3 years before the first dose.
- History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active brain metastasis.
- Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula.
- Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
- Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
- Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
- Uncontrolled infection.
- Received live vaccines within 28 days before the first dose, or plan to receive live vaccines during the study period.
- Toxicity of previous anti-tumor treatment has not fully or partially recovered.
- Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
- Pregnant and/or lactating women, or planning to become pregnant during the study period.
- Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dosisstigeringskohorte 2
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dosisstigningskohorte 3
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dosis-eskaleringskohorte 4
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dosis-eskaleringskohorte 5
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dosiseskaleringskohorte 6
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dose escalation cohort 1
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dose optimization cohort 1
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Eksperimentel: Dose optimization cohort 2
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc (Safety and tolerability of JSKN021)
Tidsramme: From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc.; abnormalities in physical examinations, laboratory tests, electrocardiograms, and other safety measures.
|
From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
|
|
Dose-limiting toxicity (DLT)
Tidsramme: 21 days from the first dose
|
Incidence of dose-limiting toxicity (DLT) in each dose group.
|
21 days from the first dose
|
|
Optimal biological dose (OBD) and/or recommended Phase Ⅱ dose (RP2D) of JSKN021.
Tidsramme: Up to 24 months
|
Based on safety and efficacy data.
|
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate (ORR)
Tidsramme: Up to 24months
|
Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1）
|
Up to 24months
|
|
Duration of response (DoR)
Tidsramme: Up to 24months
|
Duration of response (DoR) assessed according to RECIST v1.1.
|
Up to 24months
|
|
Disease control rate (DCR)
Tidsramme: Up to 24months
|
Disease control rate (DCR) assessed according to RECIST v1.1.
|
Up to 24months
|
|
Progression-Free Survival (PFS)
Tidsramme: Up to 24months
|
Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression or death due to any cause (whichever occurs first).
|
Up to 24months
|
|
Overall survival(OS)
Tidsramme: Up to 24months
|
Overall Survival (OS) is defined as the time from the date of initial administration till death due to any cause.
|
Up to 24months
|
|
Immunogenicity
Tidsramme: Up to 24months
|
Incidence and titer changes of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs, if applicable)
|
Up to 24months
|
|
Maximum concentration (Cmax) of JSKN021
Tidsramme: Up to 24months
|
Maximum concentration (Cmax) of JSKN021
|
Up to 24months
|
|
Time to maximum concentration (Tmax) of JSKN021
Tidsramme: Up to 24 months.
|
Time to maximum concentration (Tmax) of JSKN021
|
Up to 24 months.
|
|
Trough concentration (Ctrough) of JSKN021
Tidsramme: Up to 24 months
|
Trough concentration (Ctrough) of JSKN021
|
Up to 24 months
|
|
Area under the concentration-time curve of JSKN021
Tidsramme: Up to 24 months
|
Area under the concentration-time curve of JSKN021
|
Up to 24 months
|
|
Volume of distribution (V) of JSKN021
Tidsramme: Up to 24 months
|
Volume of distribution (V) of JSKN021
|
Up to 24 months
|
|
Elimination half-life (t1/2) of JSKN021
Tidsramme: Up to 24 months
|
Elimination half-life (t1/2) of JSKN021
|
Up to 24 months
|
|
Clearance (CL) of JSKN021
Tidsramme: Up to 24 months
|
Clearance (CL) of JSKN021
|
Up to 24 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
2. juni 2026
Primær færdiggørelse (Anslået)
31. oktober 2028
Studieafslutning (Anslået)
31. maj 2029
Datoer for studieregistrering
Først indsendt
20. maj 2026
Først indsendt, der opfyldte QC-kriterier
29. maj 2026
Først opslået (Faktiske)
1. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
No individual participant data will be shared.
The informed consent form does not include provisions for sharing de-identified participant-level data with researchers outside the study team.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .